mantle cell lymphoma (Cancer)
Information
- Disease name
- mantle cell lymphoma
- Disease ID
- DOID:0050746
- Description
- "A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles." [url:http\://en.wikipedia.org/wiki/Mantle_cell_lymphoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04718883 | Active, not recruiting | Phase 2 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma | January 13, 2021 | August 7, 2028 |
| NCT03997968 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | October 9, 2019 | December 30, 2024 |
| NCT03282396 | Active, not recruiting | Phase 2 | Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma | June 8, 2020 | February 28, 2026 |
| NCT01865110 | Active, not recruiting | Phase 3 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | November 2013 | August 2025 |
| NCT01880567 | Active, not recruiting | Phase 2 | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | July 15, 2013 | July 31, 2024 |
| NCT03162536 | Active, not recruiting | Phase 1/Phase 2 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | June 26, 2017 | September 12, 2025 |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT03939182 | Active, not recruiting | Phase 1 | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | May 29, 2019 | May 2025 |
| NCT04600804 | Active, not recruiting | The Role of 18F-FDG-PET for Staging and Prognostication | October 30, 2020 | June 2024 | |
| NCT03863184 | Active, not recruiting | Phase 2 | Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | October 11, 2019 | September 2027 |
| NCT02339922 | Active, not recruiting | Phase 2 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | May 19, 2016 | January 6, 2031 |
| NCT04599634 | Active, not recruiting | Phase 1 | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | December 16, 2021 | February 8, 2027 |
| NCT04566887 | Active, not recruiting | Phase 2 | Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma | March 1, 2021 | November 30, 2028 |
| NCT02427620 | Active, not recruiting | Phase 2 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | June 3, 2015 | June 30, 2025 |
| NCT02446236 | Active, not recruiting | Phase 1 | Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | June 18, 2015 | December 2024 |
| NCT02471391 | Active, not recruiting | Phase 2 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) | July 22, 2015 | June 2025 |
| NCT03494179 | Active, not recruiting | Phase 1/Phase 2 | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) | April 2, 2018 | December 31, 2023 |
| NCT03740529 | Active, not recruiting | Phase 1/Phase 2 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | November 16, 2018 | January 2028 |
| NCT02558816 | Active, not recruiting | Phase 1/Phase 2 | A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients | October 14, 2015 | October 2025 |
| NCT02632396 | Active, not recruiting | Phase 1/Phase 2 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | March 1, 2016 | August 2024 |
| NCT03410901 | Active, not recruiting | Phase 1 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | April 9, 2018 | October 10, 2024 |
| NCT03523975 | Active, not recruiting | Phase 1 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | December 24, 2018 | December 2024 |
| NCT02682641 | Active, not recruiting | Phase 2 | Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL | May 18, 2016 | December 2024 |
| NCT03623373 | Active, not recruiting | Phase 2 | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | November 29, 2018 | February 5, 2025 |
| NCT04450069 | Active, not recruiting | Phase 1 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | August 14, 2020 | June 2024 |
| NCT03872180 | Active, not recruiting | Phase 2 | Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | April 11, 2019 | April 30, 2026 |
| NCT03891355 | Active, not recruiting | Phase 2 | Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL | September 30, 2019 | December 8, 2022 |
| NCT03710772 | Active, not recruiting | Phase 2 | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | May 1, 2019 | May 22, 2025 |
| NCT01661881 | Active, not recruiting | Phase 2 | Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma | August 16, 2012 | March 2025 |
| NCT03674411 | Active, not recruiting | Phase 2 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | January 2, 2019 | June 28, 2024 |
| NCT05214183 | Active, not recruiting | Phase 2 | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma | December 15, 2021 | January 2027 |
| NCT04716075 | Active, not recruiting | Phase 2 | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | August 19, 2019 | September 30, 2024 |
| NCT04191187 | Active, not recruiting | Phase 2 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | December 6, 2019 | February 2025 |
| NCT04115631 | Active, not recruiting | Phase 2 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | December 13, 2019 | March 31, 2025 |
| NCT04082936 | Active, not recruiting | Phase 1/Phase 2 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | September 30, 2019 | October 2024 |
| NCT02896582 | Active, not recruiting | Phase 2 | Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance | October 2016 | March 2025 |
| NCT04783415 | Active, not recruiting | Phase 2 | Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | March 26, 2021 | September 20, 2025 |
| NCT03088878 | Active, not recruiting | Phase 1/Phase 2 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | January 3, 2018 | August 30, 2024 |
| NCT03834688 | Active, not recruiting | Phase 2 | Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age | January 13, 2020 | November 2024 |
| NCT03478514 | Active, not recruiting | Phase 2 | Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | September 11, 2018 | December 2025 |
| NCT04765111 | Active, not recruiting | Phase 2 | Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | June 30, 2021 | August 30, 2026 |
| NCT01776840 | Active, not recruiting | Phase 3 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | May 2013 | June 2024 |
| NCT05776134 | Available | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | |||
| NCT01109069 | Completed | Phase 2 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | June 2010 | April 26, 2019 |
| NCT01148108 | Completed | Phase 2 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | June 2010 | September 2012 |
| NCT00005780 | Completed | Phase 2 | Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma | June 1, 2000 | June 16, 2021 |
| NCT01184885 | Completed | Early Phase 1 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | July 2010 | April 2013 |
| NCT00119730 | Completed | Phase 2 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | February 2005 | December 2013 |
| NCT01236391 | Completed | Phase 2 | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | February 2011 | January 2014 |
| NCT01239875 | Completed | Early Phase 1 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | November 2010 | July 17, 2019 |
| NCT01251575 | Completed | Phase 2 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | December 1, 2010 | February 11, 2019 |
| NCT01263899 | Completed | Phase 2 | A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | December 2010 | February 2012 |
| NCT01272817 | Completed | N/A | Nonmyeloablative Allogeneic Transplant | October 2001 | October 2015 |
| NCT01300026 | Completed | Phase 1 | AMG 319 Lymphoid Malignancy FIH | April 2011 | December 2016 |
| NCT01314014 | Completed | Phase 2 | Imexon for Relapsed Follicular and Aggressive Lymphomas | May 2011 | August 2014 |
| NCT01397825 | Completed | Phase 1/Phase 2 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | August 9, 2011 | October 5, 2016 |
| NCT01399840 | Completed | Phase 1 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | June 30, 2011 | May 31, 2014 |
| NCT01410513 | Completed | Phase 1 | Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia | December 2011 | May 2014 |
| NCT01437709 | Completed | Phase 2 | Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant | September 2011 | September 12, 2023 |
| NCT05064787 | Completed | N/A | Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | March 11, 2022 | February 6, 2024 |
| NCT01456351 | Completed | Phase 3 | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | September 2003 | December 2010 |
| NCT01457144 | Completed | Phase 2 | Study of Mantle Cell Lymphoma Treatment by RiBVD | October 2011 | March 2016 |
| NCT01460134 | Completed | Phase 1 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | October 2011 | October 16, 2017 |
| NCT01472562 | Completed | Phase 2 | Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma | July 29, 2011 | July 30, 2023 |
| NCT01484015 | Completed | Phase 1 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | February 2011 | October 2012 |
| NCT01484093 | Completed | Phase 1/Phase 2 | Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma | November 29, 2011 | August 11, 2023 |
| NCT04918940 | Completed | N/A | Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma | May 21, 2021 | June 27, 2022 |
| NCT01504776 | Completed | Phase 1 | Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) | April 2011 | September 2014 |
| NCT01562977 | Completed | Phase 2 | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL | April 2011 | April 2015 |
| NCT04858568 | Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients | March 11, 2021 | January 31, 2024 | |
| NCT01597778 | Completed | Phase 3 | Double Cord Versus Haploidentical (BMT CTN 1101) | June 2012 | September 11, 2020 |
| NCT01599949 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | August 2012 | May 2015 |
| NCT01646021 | Completed | Phase 3 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | December 10, 2012 | December 15, 2016 |
| NCT01652144 | Completed | Phase 2 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | September 14, 2012 | February 13, 2015 |
| NCT01662050 | Completed | Phase 2 | Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL | March 20, 2012 | September 11, 2017 |
| NCT01665768 | Completed | Phase 2 | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma | September 2012 | August 2020 |
| NCT04833504 | Completed | Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma | July 1, 2018 | October 1, 2020 | |
| NCT01737177 | Completed | Phase 2 | Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL | July 31, 2012 | February 2, 2017 |
| NCT01739309 | Completed | Phase 2 | Study of LY2835219 for Mantle Cell Lymphoma | March 20, 2013 | September 5, 2022 |
| NCT01851551 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | September 2001 | April 2005 |
| NCT02013128 | Completed | Phase 1/Phase 2 | Ublituximab + Ibrutinib in Select B-cell Malignancies | January 6, 2014 | December 2015 |
| NCT04629430 | Completed | N/A | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT | February 19, 2021 | October 28, 2022 |
| NCT02142530 | Completed | Phase 1 | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | October 2014 | January 2018 |
| NCT02268851 | Completed | Phase 1 | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | November 2014 | August 2023 |
| NCT04564040 | Completed | Phase 1 | A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole | October 12, 2020 | December 11, 2020 |
| NCT02507336 | Completed | Phase 2 | Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 | November 24, 2015 | August 2, 2023 |
| NCT02633137 | Completed | Phase 2 | Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | December 14, 2015 | November 7, 2023 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT02728531 | Completed | Phase 1 | Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma | April 18, 2016 | August 16, 2023 |
| NCT02745769 | Completed | Phase 1 | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | October 21, 2016 | January 22, 2019 |
| NCT02756247 | Completed | Phase 1 | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | May 9, 2016 | October 6, 2022 |
| NCT04402138 | Completed | Phase 2 | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | August 7, 2020 | April 5, 2024 |
| NCT04323657 | Completed | Phase 1/Phase 2 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | March 27, 2020 | February 24, 2023 |
| NCT02840539 | Completed | Phase 2 | Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma | October 11, 2016 | December 31, 2022 |
| NCT04279405 | Completed | Phase 1 | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies | June 15, 2020 | June 1, 2023 |
| NCT00022945 | Completed | Phase 2 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | ||
| NCT02927964 | Completed | Phase 1/Phase 2 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | November 7, 2016 | May 18, 2023 |
| NCT03010358 | Completed | Phase 1/Phase 2 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | July 17, 2017 | April 29, 2021 |
| NCT04061850 | Completed | Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma | July 1, 2019 | August 31, 2020 | |
| NCT03019640 | Completed | Phase 2 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | October 10, 2017 | August 16, 2021 |
| NCT03028103 | Completed | Phase 1 | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | March 27, 2017 | November 29, 2019 |
| NCT03054883 | Completed | Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy | April 1, 2012 | December 31, 2016 | |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT03833180 | Completed | Phase 1 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | March 14, 2019 | December 18, 2023 |
| NCT03816683 | Completed | A Disease Registry of Patients With Mantle Cell Lymphoma | April 1, 2019 | March 18, 2024 | |
| NCT00201877 | Completed | Phase 2 | Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma | December 2004 | March 2012 |
| NCT00225212 | Completed | Phase 2 | Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma | November 1997 | March 2003 |
| NCT00275431 | Completed | Phase 2 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | November 2005 | December 2008 |
| NCT00285389 | Completed | Phase 2 | Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | February 2002 | December 2008 |
| NCT00406809 | Completed | Phase 1/Phase 2 | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | November 2006 | October 2016 |
| NCT00446342 | Completed | Phase 1 | Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | February 2007 | March 2009 |
| NCT00472420 | Completed | Phase 2 | A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. | June 27, 2007 | May 25, 2011 |
| NCT00477412 | Completed | Phase 1/Phase 2 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | April 3, 2007 | October 28, 2020 |
| NCT00505232 | Completed | Phase 2 | Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) | January 2006 | May 2011 |
| NCT00514475 | Completed | Phase 2 | Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | November 2005 | June 2009 |
| NCT00571493 | Completed | Phase 1/Phase 2 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma | April 14, 2006 | November 1, 2014 |
| NCT00581776 | Completed | Phase 2 | Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma | May 2005 | May 2015 |
| NCT00581854 | Completed | Phase 2 | Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma | June 2000 | March 2010 |
| NCT00586755 | Completed | Phase 2 | Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma | February 1998 | November 2008 |
| NCT00607854 | Completed | Phase 2 | Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) | February 2008 | November 2011 |
| NCT00609869 | Completed | Phase 2 | Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab | October 2007 | August 2015 |
| NCT00612183 | Completed | Phase 2 | Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma | December 2007 | September 2009 |
| NCT00633594 | Completed | Phase 1/Phase 2 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | June 2008 | November 2016 |
| NCT00644189 | Completed | Phase 1/Phase 2 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | June 2008 | July 2021 |
| NCT00722137 | Completed | Phase 3 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | May 1, 2008 | June 17, 2017 |
| NCT00737529 | Completed | Phase 2 | A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial | December 22, 2008 | November 8, 2017 |
| NCT00786851 | Completed | Phase 2 | Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | July 2008 | August 2011 |
| NCT00791011 | Completed | Phase 1 | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | February 2008 | August 2011 |
| NCT00794638 | Completed | Phase 1 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | November 2008 | May 2010 |
| NCT00807495 | Completed | Phase 2 | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | February 10, 2009 | February 13, 2013 |
| NCT00875667 | Completed | Phase 2 | A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | April 30, 2009 | October 9, 2018 |
| NCT00877006 | Completed | Phase 3 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | April 30, 2009 | March 31, 2012 |
| NCT00880815 | Completed | Phase 1 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | February 17, 2009 | May 28, 2019 |
| NCT00891839 | Completed | Phase 2 | Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma | June 2009 | May 2014 |
| NCT00901615 | Completed | Phase 1/Phase 2 | Lenalidomide and R-CHOP in B-cell Lymphoma | January 6, 2009 | November 23, 2015 |
| NCT00921414 | Completed | Phase 3 | Mantel Cell Lymphoma Efficacy of Rituximab Maintenance | September 2008 | February 2017 |
| NCT00958256 | Completed | Phase 2 | Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | August 2009 | March 2014 |
| NCT00963534 | Completed | Phase 1/Phase 2 | Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. | September 2009 | August 2017 |
| NCT00980395 | Completed | Phase 2 | Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | July 7, 2009 | August 14, 2018 |
| NCT00992446 | Completed | Phase 2 | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | September 2, 2010 | October 29, 2019 |
| NCT01000753 | Completed | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | May 30, 2005 | September 30, 2023 | |
| NCT05917964 | Completed | Phase 1 | A Food Effect Study of LP-168 Tablets in Healthy Subjects | June 21, 2023 | August 21, 2023 |
| NCT01073163 | Completed | Phase 3 | Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) | February 2010 | June 2012 |
| NCT01078142 | Completed | Phase 1/Phase 2 | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | February 2, 2010 | September 8, 2017 |
| NCT01088048 | Completed | Phase 1 | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | March 25, 2010 | April 28, 2015 |
| NCT03128359 | Completed | Phase 2 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | May 30, 2017 | September 15, 2021 |
| NCT00063713 | Completed | Phase 2 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | June 2003 | |
| NCT03188965 | Completed | Phase 1 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | July 6, 2017 | September 13, 2023 |
| NCT00075478 | Completed | Phase 3 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | October 2003 | February 2, 2014 |
| NCT00081874 | Completed | Phase 1/Phase 2 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | April 2004 | September 2006 |
| NCT03295240 | Completed | Early Phase 1 | The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | September 20, 2017 | January 22, 2024 |
| NCT03329950 | Completed | Phase 1 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | December 1, 2017 | September 13, 2022 |
| NCT00090090 | Completed | Phase 2 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | April 2004 | October 2006 |
| NCT03424603 | Completed | Phase 1 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | February 22, 2018 | March 15, 2024 |
| NCT03836768 | Completed | Phase 1 | BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma | January 11, 2019 | November 17, 2021 |
| NCT00114738 | Completed | Phase 2 | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | June 15, 2005 | August 11, 2022 |
| NCT01804686 | Enrolling by invitation | Phase 3 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | September 9, 2013 | January 29, 2027 |
| NCT06224309 | Not yet recruiting | Preliminary Assessment of [18F]BL40 in PET/CT Scans | May 2024 | October 2025 | |
| NCT06255704 | Not yet recruiting | Phase 2 | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients | March 15, 2024 | December 1, 2027 |
| NCT05004064 | Not yet recruiting | Phase 2 | Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma | January 1, 2023 | May 31, 2026 |
| NCT06252675 | Not yet recruiting | Phase 2 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | May 1, 2024 | March 31, 2028 |
| NCT05990465 | Not yet recruiting | Phase 1 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | July 2024 | July 2027 |
| NCT06049472 | Not yet recruiting | Patient Perspectives in Mantle Cell Lymphoma Clinical Research | October 2024 | October 2026 | |
| NCT06357676 | Not yet recruiting | Phase 1/Phase 2 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma | May 1, 2024 | May 1, 2029 |
| NCT06324994 | Not yet recruiting | Phase 2 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | May 1, 2024 | December 1, 2026 |
| NCT06363994 | Not yet recruiting | Phase 3 | A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL | May 25, 2024 | December 25, 2035 |
| NCT06208735 | Not yet recruiting | Phase 1 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | July 1, 2024 | August 1, 2027 |
| NCT05602363 | Recruiting | Phase 1 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | August 1, 2023 | September 2027 |
| NCT02858258 | Recruiting | Phase 3 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | July 2016 | May 2026 |
| NCT02952508 | Recruiting | Phase 2 | Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | July 26, 2017 | June 30, 2025 |
| NCT03153202 | Recruiting | Phase 1/Phase 2 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | July 14, 2017 | December 2025 |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT03267433 | Recruiting | Phase 3 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | March 6, 2018 | January 31, 2032 |
| NCT03375619 | Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells | December 1, 2017 | January 1, 2035 | |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT03501576 | Recruiting | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma | April 6, 2018 | October 22, 2024 | |
| NCT03616782 | Recruiting | Phase 2 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | December 24, 2018 | May 31, 2026 |
| NCT03622788 | Recruiting | Phase 1/Phase 2 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | August 8, 2019 | December 1, 2025 |
| NCT03676504 | Recruiting | Phase 1/Phase 2 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | September 7, 2018 | April 1, 2024 |
| NCT03842696 | Recruiting | Phase 1/Phase 2 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | February 4, 2020 | June 30, 2026 |
| NCT04072458 | Recruiting | Phase 1 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | November 5, 2020 | January 2026 |
| NCT04116437 | Recruiting | Phase 2 | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | October 15, 2019 | October 2025 |
| NCT04189757 | Recruiting | Phase 2 | Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | August 7, 2020 | June 30, 2025 |
| NCT04195633 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | January 25, 2021 | December 31, 2026 |
| NCT04223765 | Recruiting | Phase 1 | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | November 12, 2020 | March 22, 2043 |
| NCT04282018 | Recruiting | Phase 1/Phase 2 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | May 25, 2020 | December 31, 2025 |
| NCT04491370 | Recruiting | Phase 1/Phase 2 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | August 1, 2021 | August 15, 2025 |
| NCT04545762 | Recruiting | Phase 1 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | September 11, 2020 | October 31, 2024 |
| NCT04624958 | Recruiting | Phase 2 | Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL | December 1, 2020 | December 2025 |
| NCT04626791 | Recruiting | Phase 2 | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | August 3, 2021 | August 3, 2028 |
| NCT04736914 | Recruiting | Phase 2 | Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma | January 31, 2021 | February 28, 2026 |
| NCT04763083 | Recruiting | Phase 1 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | May 14, 2021 | December 2025 |
| NCT04775745 | Recruiting | Phase 1 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | July 19, 2021 | December 31, 2025 |
| NCT04802590 | Recruiting | Phase 2 | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | January 24, 2022 | September 30, 2031 |
| NCT04855695 | Recruiting | Phase 1/Phase 2 | Avo In R/R And Previously Untreated MCL | July 2, 2021 | June 1, 2026 |
| NCT04882475 | Recruiting | Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. | February 8, 2023 | December 2023 | |
| NCT04883437 | Recruiting | Phase 2 | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | September 3, 2021 | January 15, 2024 |
| NCT05006716 | Recruiting | Phase 1/Phase 2 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | September 13, 2021 | March 31, 2028 |
| NCT05020392 | Recruiting | Phase 3 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | September 14, 2021 | October 13, 2024 |
| NCT05020678 | Recruiting | Phase 1 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | August 20, 2021 | December 2038 |
| NCT05025423 | Recruiting | Phase 2 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | June 21, 2022 | September 15, 2026 |
| NCT05097443 | Recruiting | Phase 3 | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | April 15, 2021 | December 31, 2024 |
| NCT05164770 | Recruiting | Phase 3 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | March 1, 2021 | December 31, 2024 |
| NCT05245656 | Recruiting | Phase 2 | A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma | October 18, 2022 | December 31, 2029 |
| NCT05255354 | Recruiting | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | June 1, 2022 | March 11, 2027 | |
| NCT05281809 | Recruiting | Phase 2 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | April 19, 2022 | December 1, 2037 |
| NCT05294731 | Recruiting | Phase 1/Phase 2 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | March 24, 2022 | March 2027 |
| NCT05365659 | Recruiting | Phase 1 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | September 5, 2023 | September 2027 |
| NCT05429918 | Recruiting | Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years | December 30, 2020 | June 30, 2024 | |
| NCT05432635 | Recruiting | Phase 1 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | August 1, 2023 | December 30, 2028 |
| NCT05444322 | Recruiting | Early Phase 1 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | July 5, 2022 | July 10, 2025 |
| NCT05458297 | Recruiting | Phase 2 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | July 21, 2022 | April 26, 2027 |
| NCT05471843 | Recruiting | Phase 1/Phase 2 | Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | September 5, 2022 | August 2027 |
| NCT05486013 | Recruiting | Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma | May 26, 2022 | November 26, 2025 | |
| NCT05495464 | Recruiting | Early Phase 1 | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | November 18, 2022 | March 31, 2027 |
| NCT05529069 | Recruiting | Phase 2 | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | January 25, 2023 | April 28, 2027 |
| NCT05544019 | Recruiting | Phase 1 | Study of SGR-1505 in Mature B-Cell Neoplasms | April 10, 2023 | March 2026 |
| NCT05635162 | Recruiting | Phase 2 | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma | May 17, 2024 | October 2028 |
| NCT05643742 | Recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | March 10, 2023 | February 2030 |
| NCT05665062 | Recruiting | Phase 1 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | June 24, 2022 | November 2026 |
| NCT05694364 | Recruiting | Phase 1 | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | January 25, 2023 | January 2026 |
| NCT05724121 | Recruiting | Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax | March 1, 2023 | April 8, 2027 | |
| NCT05788289 | Recruiting | Phase 2 | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | March 14, 2023 | March 14, 2025 |
| NCT05833763 | Recruiting | Phase 2 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. | October 12, 2023 | April 2037 |
| NCT05861050 | Recruiting | Phase 1/Phase 2 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | August 10, 2023 | February 1, 2026 |
| NCT05887167 | Recruiting | Phase 1 | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | March 2, 2024 | December 15, 2026 |
| NCT05934838 | Recruiting | Phase 1 | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | October 4, 2023 | September 2031 |
| NCT05976763 | Recruiting | Phase 3 | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | September 8, 2023 | August 31, 2038 |
| NCT05978739 | Recruiting | Phase 2 | Evaluating Different Doses of Orelabrutinib in MCL | August 18, 2023 | May 25, 2025 |
| NCT06004167 | Recruiting | N/A | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) | January 14, 2024 | September 1, 2024 |
| NCT06014762 | Recruiting | Phase 1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | April 16, 2024 | March 2041 |
| NCT06022029 | Recruiting | Phase 1 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | October 13, 2023 | August 29, 2026 |
| NCT06026319 | Recruiting | Phase 1 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | October 26, 2023 | January 1, 2028 |
| NCT06029309 | Recruiting | Phase 1/Phase 2 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | May 3, 2024 | May 1, 2032 |
| NCT06054776 | Recruiting | Phase 2 | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | June 10, 2024 | September 30, 2026 |
| NCT06106841 | Recruiting | Phase 1/Phase 2 | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | October 5, 2023 | December 2024 |
| NCT06151730 | Recruiting | Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study | January 5, 2024 | December 1, 2025 | |
| NCT06192888 | Recruiting | Phase 1 | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | January 8, 2024 | January 8, 2028 |
| NCT06339255 | Recruiting | Italian Observational Study on CAR-T Therapy for Lymphoma | October 30, 2019 | December 31, 2029 | |
| NCT06340737 | Recruiting | Phase 1 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | March 29, 2024 | April 2031 |
| NCT06341556 | Recruiting | Phase 2 | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma | April 2024 | June 2028 |
| NCT04368702 | Suspended | N/A | CONFIRM: Magnetic Resonance Guided Radiation Therapy | May 1, 2021 | June 18, 2024 |
| NCT06263491 | Suspended | Phase 2 | Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | May 29, 2024 | March 1, 2027 |
| NCT01500538 | Terminated | Phase 2 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | October 2012 | May 2014 |
| NCT00847223 | Terminated | Phase 2 | Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma | June 2007 | March 2009 |
| NCT00714259 | Terminated | Phase 2/Phase 3 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | July 2008 | February 2013 |
| NCT03685344 | Terminated | Phase 1 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | February 4, 2019 | October 27, 2020 |
| NCT03601819 | Terminated | Phase 1 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | May 15, 2019 | July 17, 2020 |
| NCT03585725 | Terminated | Early Phase 1 | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma | September 26, 2018 | July 22, 2020 |
| NCT03436771 | Terminated | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | February 19, 2018 | July 20, 2018 | |
| NCT01578343 | Terminated | Phase 2 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma | June 2012 | February 2016 |
| NCT03311126 | Terminated | Phase 2 | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | October 19, 2017 | July 31, 2023 |
| NCT03272633 | Terminated | Early Phase 1 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | October 26, 2020 | September 22, 2022 |
| NCT03229382 | Terminated | Phase 2 | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse | May 14, 2018 | January 31, 2020 |
| NCT03151057 | Terminated | Phase 1 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | July 31, 2018 | July 20, 2022 |
| NCT01021423 | Terminated | Phase 3 | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). | April 1, 2010 | March 1, 2011 |
| NCT02877082 | Terminated | Phase 2 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | September 2016 | July 2017 |
| NCT04176913 | Terminated | Phase 1 | Study of LUCAR-20S in Patients With R/R NHL | December 1, 2020 | December 9, 2021 |
| NCT05107856 | Terminated | Phase 1 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | March 22, 2022 | January 19, 2024 |
| NCT04358458 | Terminated | Phase 1/Phase 2 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | March 24, 2020 | July 28, 2023 |
| NCT02793583 | Terminated | Phase 2/Phase 3 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | May 25, 2016 | July 4, 2022 |
| NCT04419389 | Terminated | Phase 1/Phase 2 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | March 2, 2021 | August 24, 2021 |
| NCT02483000 | Terminated | Phase 1 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | February 1, 2017 | September 2, 2020 |
| NCT02356458 | Terminated | Phase 1/Phase 2 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | August 31, 2015 | March 30, 2021 |
| NCT05611853 | Terminated | Phase 1/Phase 2 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | November 25, 2022 | December 25, 2023 |
| NCT00275262 | Terminated | Phase 2 | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | February 2006 | |
| NCT04692155 | Terminated | Phase 1/Phase 2 | Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) | August 31, 2021 | June 30, 2022 |
| NCT01799889 | Terminated | Phase 2 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | March 14, 2013 | January 30, 2020 |
| NCT01796470 | Terminated | Phase 2 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | June 20, 2013 | December 22, 2016 |
| NCT00022971 | Terminated | Phase 1 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | August 15, 2001 | March 17, 2017 |
| NCT00942409 | Terminated | Phase 2 | Study of Repeat Intranodal Injections of Ad-ISF35 | June 2009 | July 2014 |
| NCT01744912 | Terminated | Phase 1 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | November 21, 2012 | February 7, 2014 |
| NCT00183989 | Terminated | Phase 2 | Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma | August 2000 | December 2006 |
| NCT01728207 | Terminated | Phase 1 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | March 2013 | March 2017 |
| NCT00843050 | Terminated | Phase 2 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma | November 2009 | August 2012 |
| NCT01685606 | Terminated | Phase 2 | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma | March 2013 | June 2015 |
| NCT04844086 | Terminated | Phase 1 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | March 2, 2021 | May 12, 2022 |
| NCT01111188 | Terminated | Phase 1 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | August 23, 2010 | April 12, 2019 |
| NCT03684694 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | December 1, 2018 | November 8, 2022 |
| NCT05003141 | Unknown status | Phase 1 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | November 15, 2021 | January 2024 |
| NCT04407845 | Unknown status | Atrial Fibrillation in Patients Receiving Ibrutinib | May 21, 2020 | November 30, 2022 | |
| NCT03999697 | Unknown status | Phase 1 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | December 1, 2018 | December 1, 2020 |
| NCT03016988 | Unknown status | Phase 2 | The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma | January 2017 | December 2020 |
| NCT02892695 | Unknown status | Phase 1/Phase 2 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | September 2016 | September 2019 |
| NCT04109872 | Unknown status | Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results. | September 15, 2018 | July 15, 2020 | |
| NCT01439750 | Unknown status | Phase 1 | Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) | May 2012 | August 2020 |
| NCT04127916 | Unknown status | Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) | January 30, 2020 | December 31, 2020 | |
| NCT04184414 | Unknown status | Early Phase 1 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | January 9, 2018 | January 1, 2020 |
| NCT01449344 | Unknown status | Phase 3 | Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | May 9, 2009 | December 2018 |
| NCT02858804 | Unknown status | Phase 4 | EDOCH Alternating With DHAP for New Diagnosed Younger MCL | January 2016 | June 2020 |
| NCT05076097 | Unknown status | Phase 2 | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma | September 30, 2021 | October 15, 2023 |
| NCT04952974 | Unknown status | B-cell Chronic Lymphoid Malignancies Markers | June 14, 2021 | March 30, 2023 | |
| NCT00310037 | Unknown status | Phase 2 | Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma | June 2006 | |
| NCT02851589 | Unknown status | Phase 1/Phase 2 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | July 2016 | November 2019 |
| NCT03629873 | Unknown status | Phase 2 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | February 1, 2018 | December 31, 2021 |
| NCT02081937 | Unknown status | Phase 1/Phase 2 | CART-19 Immunotherapy in Mantle Cell Lymphoma | March 2014 | December 2019 |
| NCT02819583 | Unknown status | Phase 1/Phase 2 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | October 2016 | September 2019 |
| NCT02354313 | Unknown status | Phase 3 | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients | May 2010 | January 2019 |
| NCT02267590 | Unknown status | Tissue Collection for Biomarkers Determining Resistance to Ibrutinib | October 2014 | October 2016 | |
| NCT01460602 | Withdrawn | Phase 1/Phase 2 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | May 2010 | October 2014 |
| NCT01170052 | Withdrawn | Phase 1/Phase 2 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | May 2010 | April 2014 |
| NCT04231734 | Withdrawn | N/A | Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma | April 2023 | September 2026 |
| NCT03232307 | Withdrawn | Phase 2 | Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma | July 1, 2019 | July 1, 2021 |
| NCT04665115 | Withdrawn | Phase 2 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | November 23, 2020 | July 22, 2022 |
| NCT03617484 | Withdrawn | Phase 2 | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | July 2020 | July 2030 |
| NCT02735876 | Withdrawn | Phase 3 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | May 2016 | |
| NCT04849715 | Withdrawn | Phase 3 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | March 11, 2022 | July 7, 2034 |
| NCT03579927 | Withdrawn | Phase 1/Phase 2 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | October 3, 2019 | October 3, 2019 |
| NCT04043845 | Withdrawn | Phase 1 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | February 3, 2020 | February 3, 2020 |
| NCT00541424 | Withdrawn | Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma | September 2007 | November 2008 | |
| NCT05934097 | Withdrawn | Phase 1 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | December 2022 | May 2039 |
- Disase is a (Disease Ontology)
- DOID:707
- Cross Reference ID (Disease Ontology)
- GARD:6969
- Cross Reference ID (Disease Ontology)
- ICDO:9673/3
- Cross Reference ID (Disease Ontology)
- MESH:D020522
- OrphaNumber from OrphaNet (Orphanet)
- 52416
- ICD10 preferred id (Insert disease from ICD10)
- D0002245
- ICD10 class code (Insert disease from ICD10)
- C83.1